During the past five years, the reality of the cannabis industry has not lived up to the hype that accompanied Canada's ...

The stock's rise snapped a three-day losing streak.

During the past five years, investing in cannabis stocks has led to dreadful returns for investors. One of the top cannabis ...

Tilray's shares plunge 10% on revenue miss and cash burn concerns, risking further dilution and potential reverse split below ...

During the past five years, investing in cannabis stocks has led to dreadful returns for investors. One of the top cannabis stocks in the industry is Tilray Brands (TLRY-0.89%), and during that ...

Q2 2025 Earnings Call Transcript January 9, 2025 Operator: Thank you for joining us for today’s conference call to discuss ...

Shares of Tilray Brands Inc. TLRY slid 3.42% to $1.13 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.28% to ...

Tilray cultivates and sells cannabis in Canada and exports into the global medical market. It also sells CBD and alcohol. The company is the result of legacy Aphria acquiring legacy Tilray in a ...

Tilray Brands (NASDAQ:TLRY) traded ~8% lower in the premarket on Friday after the Canadian cannabis company fell short of ...

Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), proudly announces that its German subsidiary, Tilray Deutschland GmbH, has secured a tender to supply Luxembourg with its ...

Tilray Brands reported 9% YoY revenue growth in Q2 2025 to $210.95 million. Fiscal 2025 guidance remains strong at $950 million-$1 billion in net revenue targets.